Astrotech Corporation (ASTC) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, ASTC carries an RQD Score of 28 out of 100, a letter grade of E, and a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars score as follows: Fundamental Cash Engine 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow 3/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are the two that measure whether the business generates value and whether informed capital is building positions. The cash engine pillar reflects a negative return on invested capital and a 0% free cash flow yield, meaning the reported financials do not currently show a self-funding operation. The flow pillars indicate little evidence of supportive institutional or insider conviction in the source data. The balance-sheet pillar is middling rather than distressed: the Altman Z-Score of 2.5 and Debt/Equity of 0.5 sit in the range the rating treats as neutral, but a Piotroski F-Score of 3 out of 9 points to weak financial-quality signals. Beta of 1.0 places macro sensitivity at market-average, so the rating's macro pillar does not add a directional penalty beyond sector exposure.

Upside drivers implied by the data would have to come from a turnaround in operating performance, which the reported trend does not yet show. Valuation tradeoffs are difficult to assess because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data; the shares trade at a $11.1M market capitalization against negative operating and net margins. The 52-week range of $1.92 - $68.85 is extremely wide and should be weighed as evidence of volatility rather than as a valuation anchor.

Per the SEC financials, reported revenue moved from $0.8M (FY 2023) to $1.7M (FY 2024) before declining to $1.0M (FY 2025), while operating losses widened each year, reaching $-14.7M in FY 2025. Per the market data section, ROIC is -35% and FCF yield is 0%. The Roarable RQD rating reports an Altman Z-Score of 2.5, a Piotroski F-Score of 3 out of 9, and a Debt/Equity ratio of 0.5. Cash and debt balances are not available in source data for any period.

Per the recent news and catalysts section, the most recent headline reports an Astrotech proposal to provide lunar power infrastructure under a NASA program, flagged YELLOW. A second headline states that at least $20M in sale value is needed for first bonuses under a new plan, flagged YELLOW. A Form 4 filing by director Tom Wilkinson is listed, flagged YELLOW. A "Risk Watch" item titled "Discipline and Rules-Based Execution in ASTC Response" is flagged RED. A price-action item reports the stock slipping 1.92% to $5.10, and a Manila Times item references an appointment of a Chief Financial Officer at Innventure, a separate entity, which the source does not connect to ASTC operationally. The proprietary signals list in the Butterfly graph is empty.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are therefore not available in source data. The only sector-level context provided is the Health Care sector and Biotechnology: Laboratory Analytical Instruments industry classification. A prospective investor should watch whether the NASA-related lunar infrastructure proposal translates into revenue, since the source does not establish any link between that activity and the reported health-care industry classification.

• What drives the reported revenue increase in FY 2024 and subsequent decline in FY 2025, and what products or services generate it?
• What are the cash and debt balances, since both are listed as N/A across all reported periods?
• What is the relationship between the NASA lunar power proposal and the company's reported health-care industry classification?
• What is the status and size of the new bonus plan referenced in the news flow, and how does it affect dilution or cash burn?
• Given the Beta of 1.0 and the wide 52-week range, what explains the extreme price volatility in the source period?